
    
      This randomized, double-blind, vehicle-controlled, dose-ranging, parallel-group multi-site
      study is designed to evaluate the therapeutic efficacy and safety of the investigational
      product, DSXS, for the treatment of moderate to severe scalp psoriasis at different
      application times up to 30 minutes.
    
  